Citi analyst Geoff Meacham raised the firm’s price target on AbbVie (ABBV) to $226 from $215 and keeps a Buy rating on the shares. AbbVie reported another solid quarter, says Citi, which remains bullish on the shares, citing the company’s many pipeline events and good commercial momentum for 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Reports Solid Q3 2024 Financial Performance
- Alphabet, AMD report Q3 earnings beats: Morning Buzz
- AbbVie: Shift in Humira sales volume to biosimilar ‘playing out as anticipated’
- ABBV Earnings: AbbVie Reports Strong Q3 Results, Raises Outlook
- AbbVie raises FY24 revenue view to ~$56B from ~$55.5B, consensus $55.73B